Jump to Navigation
Trends and Sentiments
Comments and Analysis
Apple Defends The Irish Tax Arrangement That Allegedly...
My Dividend Portfolio: Adding Nike
Eurozone inflation near five-year low
Ukraine Told to Pay $3.9 Billion to Resume Gas Supplies
Devon Energy And Cimarex Energy Drive Cana's Strong...
The Agricultural Enigma - Will Low Grain Prices Lead To...
Canadian exchange TMX names new chief executive
Outside the Box: 3 stock-market pros are saying this to...
Toyota: One Of The Best Plays On Yen Devaluation
3 ways successful business owners avoid taking risks
Emisphere: Crown Jewel In Oral B12
Analyzing Wednesday's Noteworthy Insider Buys And Sells
7 Healthcare Stocks With January Catalysts
Analyzing Friday's Noteworthy Insider Buys And Sells
Novel Cancer Treatment Gains Acceptance
Targeted Chemotherapy: The Perfect Balance Between Safety And Efficacy?
Hyper-Novel Investments For Targeting Cancer
Notable Micro Cap Insider Buys Last Week
Biotechnology And Drug Stocks Up For FDA Approval In August
Delcath Systems 's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Cancer Treatment Need Is The Mother Of Novel Solutions
Delcath Systems: An Exclusive Interview With ROTH Capital Senior Analyst
Interview: Delcath's CEO Provides Details About The Resubmission Of The FDA's New Drug Application For CHEMOSAT
Delcath Systems: A Frustrating Stock With Quite A Bit Of Value Potential
Biotech Weekend Recap: Bears, Bears Everywhere
Delcath Systems Management Discusses Q3 2012 Results - Earnings Call Transcript
Delcath Systems' CEO Presents at Lazard Capital Markets 9th Annual Healthcare Conference (Transcript)
Q3 2012 Pharma Company Updates Indicate Upcoming Catalysts
Three Reasons Delcath Systems Appears Undervalued
Is Delcath The Post-Celsion Play On Liver Cancer?
Cancer Radiation Stocks To Consider: Delcath, Spectrum And IsoRay
The Business Of Cancer
Delcath Systems: 'Improving The Bicycle' In Chemotherapy
Delcath Systems: Bullish On Melblez FDA Panel Vote And Subsequent Approval
Wonga profits halve after being hit by tougher...
It Is UGLY In Italy
EUR/GBP: 1.2854 USD/EUR: 1.2598 JPY/USD: 109.626
Bullfax.com - Market News & Analysis 2008-2011
Terms & Conditions